Indonesia's medical device manufacturing sector is growing as the government pushes for domestic production to reduce the country's 90%+ import dependency for medical devices. Kemenkes and Kemenperin have established incentives for local manufacturing, and the COVID-19 pandemic demonstrated the strategic importance of domestic medical device capabilities. AI is being adopted for quality control, regulatory compliance automation, and production optimization as Indonesian manufacturers like PT Oneject and PT Biosensors Indonesia scale up to serve the massive BPJS healthcare market.
Indonesia's medical device manufacturing ecosystem is nascent compared to established hubs in China, Germany, or the US, meaning AI applications must account for smaller production volumes and less mature quality systems. The regulatory pathway through Kemenkes for AI-enhanced medical devices is not yet well-defined, creating approval uncertainty. Sourcing of precision components locally remains difficult, and TKDN requirements may not always be achievable for advanced AI-integrated devices. The limited pool of biomedical engineers with AI expertise constrains innovation capacity.
Kemenkes regulates medical device registration through Permenkes on Medical Device Distribution Permits (izin edar). BPOM oversees in-vitro diagnostic devices. The ASEAN Medical Device Directive (AMDD) harmonization influences Indonesian standards, with Kemenkes adopting CSDT (Common Submission Dossier Template) requirements. TKDN mandates minimum domestic content for medical devices sold to government hospitals. AI-powered medical devices may require additional clinical evidence under Kemenkes risk classification that categorizes devices into four risk classes.
We understand the unique regulatory, procurement, and cultural context of operating in Indonesia
Indonesia's 2022 data protection law requiring data processors to obtain consent and implement security measures. Applies to AI systems handling personal data. Enforcement began 2024 with penalties up to 6 billion rupiah.
BRIN (National Research and Innovation Agency) guidelines emphasizing transparency, accountability, and human-centric AI development. Voluntary framework for responsible AI deployment across sectors.
Financial services data (banking, insurance) must be stored in Indonesia per OJK regulations. Government Regulation 71/2019 requires public sector data to remain in-country. Private sector data can use cloud providers with Indonesia regions (AWS Jakarta, Google Cloud Jakarta).
Enterprise procurement cycles 4-6 months with heavy emphasis on relationship building. State-owned enterprises (BUMN) follow formal tender processes requiring local partnership or presence. Private sector decision-making involves multiple stakeholder approval (finance, IT, business units, legal). Budget approvals centralized at group/holding company level for >500M IDR.
Prakerja program provides skills training subsidies for workers. Ministry of Industry offers Industry 4.0 readiness grants. Limited direct AI adoption subsidies compared to Singapore/Malaysia. Corporate training often funded directly by enterprises. Tax incentives available for R&D activities including AI development.
High power distance culture requires engagement with senior leadership first. Relationship building essential before business discussions. Bahasa Indonesia training delivery required despite English proficiency in management. Consensus-driven decision making involves broad stakeholder input. Regional diversity (Java, Sumatra, Sulawesi) requires localized approaches.
Explore articles and research about AI implementation in this sector and region
Article
A guide to Microsoft Copilot courses for Indonesian companies in 2026. Corporate training for M365 organisations in Jakarta and across Indonesia.
Article
A guide to ChatGPT courses for Indonesian companies in 2026. Corporate workshops in Jakarta, Surabaya, and Bandung. Kartu Prakerja eligible options and in-house training programmes.
Article
Indonesia's Personal Data Protection Law (UU PDP), fully effective since October 2024, is modeled on GDPR and applies to all AI systems processing personal data. With mandatory AI regulations expected in early 2026, companies must comply now.
Article
A guide to the best AI courses for Indonesian companies in 2026 — from Kartu Prakerja eligible programmes to corporate workshops in Jakarta, Surabaya, and Bandung.
Our team has trained executives at globally-recognized brands
YOUR PATH FORWARD
Every AI transformation is different, but the journey follows a proven sequence. Start where you are. Scale when you're ready.
ASSESS · 2-3 days
Understand exactly where you stand and where the biggest opportunities are. We map your AI maturity across strategy, data, technology, and culture, then hand you a prioritized action plan.
Get your AI Maturity ScorecardChoose your path
TRAIN · 1 day minimum
Upskill your leadership and teams so AI adoption sticks. Hands-on programs tailored to your industry, with measurable proficiency gains.
Explore training programsPROVE · 30 days
Deploy a working AI solution on a real business problem and measure actual results. Low risk, high signal. The fastest way to build internal conviction.
Launch a pilotSCALE · 1-6 months
Roll out what works across the organization with governance, change management, and measurable ROI. We embed with your team so capability transfers, not just deliverables.
Design your rolloutITERATE & ACCELERATE · Ongoing
AI moves fast. Regular reassessment ensures you stay ahead, not behind. We help you iterate, optimize, and capture new opportunities as the technology landscape shifts.
Plan your next phaseThe government's target to increase domestic medical device production from less than 10% to a much larger share of the market creates demand for AI-powered manufacturing optimization in new and expanding facilities. AI quality control systems help Indonesian manufacturers meet international standards (ISO 13485) required for both domestic BPJS procurement and export markets. Kemenperin provides incentive packages for medical device manufacturers adopting Industry 4.0 technologies including AI-driven production monitoring.
Kemenkes is developing guidance on software as a medical device (SaMD) that will affect AI-integrated products, though the regulatory framework is still evolving. Currently, AI-powered diagnostic devices are classified based on their intended use and risk level under existing Permenkes categories. Manufacturers must provide clinical evidence demonstrating AI performance, which ideally includes validation data from Indonesian patient populations. The ASEAN harmonization process may eventually provide a regional framework for AI medical device regulation that Indonesia adopts.
Let's discuss how we can help you achieve your AI transformation goals.
